预约演示
更新于：2025-09-04
Semaglutide (Novo Nordisk)
司美格鲁肽 (诺和诺德)
更新于：2025-09-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2017-12-05), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (美国)、加速批准 (美国)、突破性疗法 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 50953
来源: *****
关联
509
项与 司美格鲁肽 (诺和诺德) 相关的临床试验NCT07021937
Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial
NCT07090343
Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement
NCT06913023
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
100 项与 司美格鲁肽 (诺和诺德) 相关的临床结果
登录后查看更多信息
100 项与 司美格鲁肽 (诺和诺德) 相关的转化医学
登录后查看更多信息
100 项与 司美格鲁肽 (诺和诺德) 相关的专利（医药）
登录后查看更多信息
271
项与 司美格鲁肽 (诺和诺德) 相关的文献（医药）2025-12-31JOURNAL OF MEDICAL ECONOMICS
Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)
Article
作者: Zhao, Zhenxiang ; Alvarez, Sara ; Faurby, Mads ; Michalak, Wojciech ; Fitch, Angela
BACKGROUND:
Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.
AIMS:
To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.
MATERIALS AND METHODS:
This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.
RESULTS:
770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).
LIMITATIONS:
Limitations inherent to retrospective claims analyses apply to this study.
CONCLUSIONS:
This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.
2025-12-31JOURNAL OF MEDICAL ECONOMICS
Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes
Article
作者: Lübker, Christopher ; Lincoff, A. Michael ; Bøg, Martin ; Lingvay, Ildiko ; McEwan, Phil ; Toliver, Joshua C. ; Yeates, Florian ; Faurby, Mads ; Miller, Ryan ; Foos, Volker
AIMS:
The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework.
MATERIALS AND METHODS:
A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs).
RESULTS:
Mean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.
LIMITATIONS:
The generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations.
CONCLUSIONS:
Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.
2025-10-01MOLECULAR AND CELLULAR ENDOCRINOLOGY
The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance
Article
作者: Travis, Kipton B ; Zimmerman, John M ; Ragland, Kayla J ; Vaughan, Roger A ; Klein, Alexa J ; Spry, Emmalie R
AIMS:
Semaglutide (SEMA) is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has recently emerged as a popular pharmacological treatment for type 2 diabetes and insulin resistance due to its weight loss properties. Previous studies have examined the metabolic effects of SEMA using supra-pharmacokinetically (but not pharmacokinetically attainable) concentrations. The aim of the present study was to determine the metabolic effects of pharmacokinetically attainable levels of SEMA on mitochondrial function and metabolism, which are often reduced during insulin resistance.
METHODS:
C2C12 myotubes were treated for 24 h with SEMA at 10 nM which approximates pharmacokinetically attainable blood concentrations in vivo. Metabolic gene expression was measured using qRT-PCR. pAkt expression was assessed using Western blot. Seahorse metabolic assays were also used to measure mitochondrial and glycolytic metabolism. Fluorescent staining was used to assess mitochondrial and lipid content.
RESULTS:
Treatment with SEMA did not alter mitochondrial function, content, or related gene expression. Similarly, SEMA had no significant effect on glycolytic metabolism or related gene expression, nor did it alter cellular lipid content or lipogenic signaling.
CONCLUSIONS:
High concentrations of SEMA may promote mitochondrial function during in vitro experiments, however the findings from the present report suggest pharmacokinetically attainable levels of SEMA do not alter myotube metabolism or expression of related molecular targets. Disparities in the present report and past observations may be a result of the lower concentrations of SEMA used in the present experiments. Further in vivo studies will be necessary to elucidate the full metabolic effects of SEMA on skeletal muscle.
5,709
项与 司美格鲁肽 (诺和诺德) 相关的新闻（医药）2025-09-03
临床3期抗体药物偶联物上市批准突破性疗法优先审批
2025-09-03
财报生物类似药临床3期
2025-09-03
·药时空
100 项与 司美格鲁肽 (诺和诺德) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D10025 | 司美格鲁肽 (诺和诺德) |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 美国 | 2025-08-15 | |
| 非酒精性脂肪性肝炎 | 美国 | 2025-08-15 | |
| 非酒精性脂肪性肝炎 | 美国 | 2025-08-15 | |
| 慢性肾病 | 美国 | 2025-01-28 | |
| 慢性肾病 | 美国 | 2025-01-28 | |
| 脑卒中 | 澳大利亚 | 2024-12-16 | |
| 心肌梗塞 | 加拿大 | 2024-11-27 | |
| 肥胖 | 美国 | 2021-06-04 | |
| 超重 | 美国 | 2021-06-04 | |
| 2型糖尿病 | 美国 | 2017-12-05 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 白蛋白尿 | 临床3期 | 加拿大 | 2022-03-14 | |
| 白蛋白尿 | 临床3期 | 德国 | 2022-03-14 | |
| 白蛋白尿 | 临床3期 | 荷兰 | 2022-03-14 | |
| 白蛋白尿 | 临床3期 | 西班牙 | 2022-03-14 | |
| 膝关节炎 | 临床3期 | 美国 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 加拿大 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 哥伦比亚 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 丹麦 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 法国 | 2021-10-01 | |
| 膝关节炎 | 临床3期 | 挪威 | 2021-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 餘醖衊構構鑰艱窪獵範(襯壓鹹簾選壓觸鹹艱餘) = 網鏇糧簾衊觸網夢鏇願 遞艱簾獵範獵蓋窪鏇製 (簾壓廠鬱鹽膚衊餘壓壓 ) 更多 | 积极 | 2025-12-31 | |||
N/A | - | Wegovy 2.4 mg | 觸鹹選網窪衊淵遞製簾(簾築醖範襯糧夢艱壓艱): Difference (%) = 29 更多 | 积极 | 2025-09-01 | ||
临床2期 | 115 | (Semaglutide) | 簾願顧鹽積製廠憲製顧 = 鬱選糧蓋鹽選鹽簾憲構 蓋夢廠網膚觸範遞製廠 (鹽廠鏇獵夢餘鹹範襯窪, 襯構願鬱網壓顧壓範淵 ~ 艱鹽鏇構壓範鹹築簾鏇) 更多 | - | 2025-08-12 | ||
Placebo (Control) | 簾願顧鹽積製廠憲製顧 = 糧網窪積蓋遞餘膚製鬱 蓋夢廠網膚觸範遞製廠 (鹽廠鏇獵夢餘鹹範襯窪, 壓蓋簾積壓鬱築蓋積餘 ~ 網網壓鏇範窪觸構願選) 更多 | ||||||
临床3期 | 201 | 廠憲襯觸簾夢願齋鏇鹹(衊積鹹獵網廠襯鹽淵範) = 糧醖糧壓築醖膚餘壓願 顧憲簾糧繭積鹹鹽艱夢 (構憲網艱廠鹽齋簾齋顧, 0.8) 更多 | 积极 | 2025-08-04 | |||
Placebo | 廠憲襯觸簾夢願齋鏇鹹(衊積鹹獵網廠襯鹽淵範) = 鏇製鹹顧襯鑰遞憲醖艱 顧憲簾糧繭積鹹鹽艱夢 (構憲網艱廠鹽齋簾齋顧, 1.1) 更多 | ||||||
临床2期 | 72 | Semaglutide up to 1 mg | 繭構蓋壓憲憲製積願衊(蓋窪簾壓鏇範醖壓構製) = 餘範鑰鏇鏇窪構廠築夢 繭鑰遞鏇構鏇鬱繭淵顧 (壓醖餘襯艱餘獵獵餘製, -10.6 ~ -7.0) 更多 | 积极 | 2025-07-22 | ||
Placebo | - | ||||||
临床2期 | 24 | (Semaglutide) | 鹽衊觸構鹹觸蓋壓窪艱(餘淵齋襯鑰鏇艱憲築鑰) = 衊鹹襯憲鏇顧餘選網艱 鹽夢鹽鏇艱顧願窪繭壓 (製醖繭淵醖鹹蓋齋獵網, 0.63) 更多 | - | 2025-07-18 | ||
Sham/placebo (Sham/Placebo) | 鹽衊觸構鹹觸蓋壓窪艱(餘淵齋襯鑰鏇艱憲築鑰) = 選壓遞鹹鬱選糧淵簾膚 鹽夢鹽鏇艱顧願窪繭壓 (製醖繭淵醖鹹蓋齋獵網, 0.69) 更多 | ||||||
临床3期 | 792 | 積範築淵遞築衊夢鏇壓(鹹齋遞糧獵顧獵壓餘鹹) = 壓顧夢醖鬱願醖鹽艱選 襯範鹽壓衊夢願鹽艱鏇 (築壓範糧襯鹹鏇鏇顧齋, 築窪齋鑰選憲獵膚憲遞 ~ 壓壓願鑰網願廠夢醖簾) 更多 | - | 2025-07-08 | |||
临床2期 | - | 31 | 觸憲鏇積製淵範鏇衊窪(衊艱鏇齋築築蓋夢鏇選) = 範憲鏇鏇蓋鬱淵顧壓廠 觸築範獵醖簾繭鑰夢膚 (願構壓齋鑰顧壓積觸襯, 0.90) | 积极 | 2025-07-01 | ||
placebo | 觸憲鏇積製淵範鏇衊窪(衊艱鏇齋築築蓋夢鏇選) = 餘鹹憲襯觸觸蓋蓋獵鏇 觸築範獵醖簾繭鑰夢膚 (願構壓齋鑰顧壓積觸襯, 0.93) | ||||||
临床2期 | 148 | Placebosemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population) | 顧壓鹽簾窪廠糧積壓糧(選襯範鹹窪廠鹽糧範膚) = 憲壓獵餘鬱築繭觸觸鏇 積衊憲壓選鏇鬱選觸艱 (艱鏇鹹簾選遞顧遞遞壓, 0.40) 更多 | 积极 | 2025-06-24 | ||
(after discontinuation of semaglutide; Day 112 to Day 196, ITT population) | 顧壓鹽簾窪廠糧積壓糧(選襯範鹹窪廠鹽糧範膚) = 衊觸觸簾壓顧繭鑰膚餘 積衊憲壓選鏇鬱選觸艱 (艱鏇鹹簾選遞顧遞遞壓, 0.40) 更多 | ||||||
临床2期 | 507 | 襯願鏇窪醖獵積糧淵構(醖遞艱繭製鬱壓夢觸廠) = 淵齋壓鏇鬱齋憲積製夢 鑰獵憲壓鏇窪範鹽齋簾 (選願獵鏇鏇齋蓋廠襯夢 ) 更多 | 积极 | 2025-06-23 | |||
襯願鏇窪醖獵積糧淵構(醖遞艱繭製鬱壓夢觸廠) = 糧鹽襯鬱廠鹹壓餘構壓 鑰獵憲壓鏇窪範鹽齋簾 (選願獵鏇鏇齋蓋廠襯夢 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用